Related Experiment Video

Updated: Jan 8, 2026

Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

28.5K

Protocol for an open labelled observational study in children & adolescents with severe asthma with an eosinophilic

Atul Gupta1,2, Ines de Mir Messa3, Jose Valverde-Molina4

  • 1Paediatric Respiratory Department, King's College Hospital, Department of Women and Children's Health, London, United Kingdom.

Plos One
|December 19, 2025
PubMed

Insights

This study assesses the real-world effectiveness of mepolizumab in children with severe eosinophilic asthma. It aims to provide crucial long-term safety and efficacy data for this patient population.

Area of Science:

  • Pediatric Pulmonology
  • Immunology
  • Pharmacology

Background:

  • Severe pediatric eosinophilic asthma presents significant risks, including exacerbations and reduced quality of life.
  • Biologic therapies targeting eosinophilic pathways offer improved management for severe asthma.
  • Mepolizumab, an anti-interleukin-5 monoclonal antibody, is approved for severe eosinophilic asthma in children aged ≥6, but pediatric real-world data are limited.

Purpose of the Study:

  • To evaluate the long-term safety and efficacy of mepolizumab in children and adolescents with severe eosinophilic asthma in real-world clinical practice.
  • To assess mepolizumab's performance in patients with comorbidities and on concomitant medications.

Main Methods:

  • An open-label, multinational, multicenter observational cohort study (CASAM) enrolling 150 pediatric patients (6-17 years) with severe asthma.
  • Data collection over 36 months (12 months pre- and 24 months post-mepolizumab initiation) using pseudonymized electronic case report forms.
  • Primary outcome: comparison of clinically significant asthma exacerbation rates pre- and post-mepolizumab treatment.

Main Results:

  • The study is designed to compare the rates of clinically significant asthma exacerbations in the pre-exposure and 12-month post-exposure periods with mepolizumab treatment.
  • Long-term safety and efficacy data in children and adolescents, including those with comorbidities, will be analyzed.

Conclusions:

  • This study will provide valuable real-world evidence on the long-term safety and efficacy of mepolizumab in pediatric severe eosinophilic asthma.
  • Findings will inform clinical decision-making and management strategies for this vulnerable patient group.
Abstract

More Related Videos

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

23.2K
Murine Model of Allergen Induced Asthma08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

41.1K

Related Concept Videos

Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
3.2K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.7K